Compass Therapeutics (CMPX) Competitors $1.37 -0.05 (-3.52%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CMPX vs. PCB, TCBX, PLRX, CRON, CGEM, PRTA, REPL, CRGX, AVXL, and CRMDShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include PCB Bancorp (PCB), Third Coast Bancshares (TCBX), Pliant Therapeutics (PLRX), Cronos Group (CRON), Cullinan Therapeutics (CGEM), Prothena (PRTA), Replimune Group (REPL), CARGO Therapeutics (CRGX), Anavex Life Sciences (AVXL), and CorMedix (CRMD). Compass Therapeutics vs. PCB Bancorp Third Coast Bancshares Pliant Therapeutics Cronos Group Cullinan Therapeutics Prothena Replimune Group CARGO Therapeutics Anavex Life Sciences CorMedix PCB Bancorp (NASDAQ:PCB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking. Is PCB or CMPX more profitable? PCB Bancorp has a net margin of 13.27% compared to Compass Therapeutics' net margin of 0.00%. PCB Bancorp's return on equity of 8.68% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PCB Bancorp13.27% 8.68% 0.87% Compass Therapeutics N/A -32.37%-30.67% Does the media prefer PCB or CMPX? In the previous week, Compass Therapeutics had 20 more articles in the media than PCB Bancorp. MarketBeat recorded 23 mentions for Compass Therapeutics and 3 mentions for PCB Bancorp. PCB Bancorp's average media sentiment score of 1.25 beat Compass Therapeutics' score of 0.48 indicating that PCB Bancorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PCB Bancorp 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor PCB or CMPX? Compass Therapeutics received 18 more outperform votes than PCB Bancorp when rated by MarketBeat users. Likewise, 73.17% of users gave Compass Therapeutics an outperform vote while only 44.44% of users gave PCB Bancorp an outperform vote. CompanyUnderperformOutperformPCB BancorpOutperform Votes1244.44% Underperform Votes1555.56% Compass TherapeuticsOutperform Votes3073.17% Underperform Votes1126.83% Which has higher valuation & earnings, PCB or CMPX? PCB Bancorp has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than PCB Bancorp, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPCB Bancorp$161.86M1.83$30.70M$1.6912.27Compass TherapeuticsN/AN/A-$42.49M-$0.37-3.70 Do institutionals and insiders believe in PCB or CMPX? 33.0% of PCB Bancorp shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 25.0% of PCB Bancorp shares are owned by insiders. Comparatively, 28.5% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate PCB or CMPX? PCB Bancorp currently has a consensus price target of $20.50, suggesting a potential downside of 1.11%. Compass Therapeutics has a consensus price target of $6.75, suggesting a potential upside of 392.70%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than PCB Bancorp.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PCB Bancorp 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Compass Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, PCB or CMPX? PCB Bancorp has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. SummaryCompass Therapeutics beats PCB Bancorp on 9 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.38M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-3.7016.1687.8613.46Price / SalesN/A282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book1.364.436.946.30Net Income-$42.49M-$41.63M$119.12M$225.93M7 Day Performance-13.84%-4.73%-1.84%-1.32%1 Month Performance-25.95%-6.53%-3.65%0.60%1 Year Performance-18.93%25.63%31.64%26.23% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics3.4294 of 5 stars$1.37-3.5%$6.75+392.7%-18.9%$195.38MN/A-3.7020PCBPCB Bancorp4.3358 of 5 stars$20.73-0.2%$20.50-1.1%+30.5%$296.32M$161.86M12.27250Insider TradePositive NewsTCBXThird Coast Bancshares1.7298 of 5 stars$35.66+0.3%$25.33-29.0%+107.3%$486.43M$274.75M13.98330Positive NewsPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090CRONCronos Group1.7856 of 5 stars$2.01-1.0%$3.00+49.3%-3.8%$776.06M$87.24M-15.46356CGEMCullinan Therapeutics1.8429 of 5 stars$12.58-4.0%$31.67+151.7%+43.6%$762.78M$18.94M0.0030Analyst RevisionPRTAProthena1.6436 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$756.01M$91.37M0.00173Analyst DowngradeAnalyst RevisionREPLReplimune Group4.2429 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A-3.68210CRGXCARGO Therapeutics1.677 of 5 stars$15.82-1.8%$30.33+91.7%+8.0%$741.51MN/A-3.71116AVXLAnavex Life Sciences3.7059 of 5 stars$8.48+2.8%$40.00+372.0%+21.1%$698.72MN/A0.0040Upcoming EarningsCRMDCorMedix2.6748 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$671.70M$60,000.00-13.2630Insider Trade Related Companies and Tools Related Companies PCB Alternatives TCBX Alternatives PLRX Alternatives CRON Alternatives CGEM Alternatives PRTA Alternatives REPL Alternatives CRGX Alternatives AVXL Alternatives CRMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMPX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
